This is consistent with a previous study demonstrating high TP53 VAF (>40%) was associated with worse OS only among patients with TP53 mutated AML treated with intensive chemotherapy, but not in those treated with HMA-based therapy [16]. The gene discussed is TP53; the disease is acute myeloid leukemia.